Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Long-term clinical outcomes after posterior-chamber phakic lens implantation for myopia

Poster Details

First Author: J.Choi SOUTH KOREA

Co Author(s):    S. Nam   D. Park   D. Lim   T. Chung           

Abstract Details

Purpose:

To report the long-term clinical outcomes including efficacy and safety after intraocular collamer lens (ICL) implantation for myopia.

Setting:

Department of Ophthalmology, Samsung Medical Center, Seoul, KoreaSungkyngwan University School of Medicine

Methods:

Medical records of 110 eye of 60 patients underwent ICL implantation at Samsung Medical Center, followed up more than 7 yearsPre- and postoperative uncorrected and corrected distant visual acuity (UDVA and CDVA), spherical equivalent, endothelial density (ECD), and intraocular pressure (IOP) were analyzed.Postoperative vault and the rate of complications including cataract and glaucoma were also evaluated.

Results:

There was significant increase in CDVA after ICL implantation, compared with CDVA before ICL implantation (P<0.01, t-test). There was no significant change in CDVA after ICL implantation.There was significant decreasing in the mean endothelial cell count after 10 years postoperatively ,but there was no significant change in IOP during follow-upDuring 10 years of follow-up, fourteen eyes developed lens opacity at 10-year follow-up. 6 eyes had taken ICL removal and phacoemulsification. Phacoemulsification was performed in 6 eyes at 10 years after ICL implantation. The rate of lens opacity and phacoemulsification are closely related with decreased vault height.

Conclusions:

The long-term clinical follow-up after ICL implantation indicates that ICL implantation has long-term stability and good refractive outcome. However, the risk of cataract increases along with the time after ICL implantation.

Financial Disclosure:

NONE

Back to Poster listing